Elevated expression of Annexin II (Lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line

Cole, Susan P.C.; Pinkoski, Michael J.; Bhardwaj, Gabu; Deeley, Roger G.

doi:10.1038/bjc.1992.103

Cited by 88 publications

(49 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results suggest that annexin IV may be one of the proteins to be induced in cells under stress conditions such as antimitotic drug exposure. Previously another annexin family member, annexin II, was shown to be overexpressed in a doxorubicin-resistant small-lung cancer cell line, H69AR (Cole et al, 1992). However, in our study, annexin II was not induced in both paclitaxel-resistant H460 cells and H460 cells …”

Section: Discussioncontrasting

confidence: 75%

“…It was previously shown that annexin II expression was elevated in doxorubicin selected MDR small-cell lung cancer cell line (Cole et al, 1992). We further examined whether annexin II or annexin IV was overexpressed in paclitaxel-resistant variants derived from H460 cells.…”

Section: Annexin IV Overexpression In Paclitaxel-resistant H460 Cell mentioning

confidence: 97%

“…Although the roles of the annexins are not well understood, they have been involved in various biological processes including inhibition of phospholipase A2, anticoagulation, endocytosis, exocytosis, inhibition of calcium channels and protein kinase C activity (Smith and Moss, 1994). It was also previously shown that annexin II was elevated in doxorubicin-resistant small-cell lung cancer cell line (Cole et al, 1992). During the course of our antimitotic research, we found that annexin IV was overexpressed in A204197-resistant human colon cancer HCT-15 cells as determined by two-dimensional protein mapping as well as mass spectroscopic analysis.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Modulation of paclitaxel resistance by annexin IV in human cancer cell lines

Han¹,

Tahir²,

Cherian³

et al. 2000

Br J Cancer

View full text Add to dashboard Cite

Efficacy of paclitaxel in cancer patients has been hampered by the ability of cells to develop paclitaxel resistance (Rowinsky et al, 1992;Rowinsky and Donehower, 1995). Therefore if we understand the mechanism of paclitaxel resistance we will be more successful in the treatment of human cancer. It has been shown that several factors contribute to paclitaxel resistance in vitro:1. P-glycoprotein (P-gp), an energy-dependent drug efflux pump shown to confer multidrug resistance (MDR) Pastan, 1988, 1993;Lehnert, 1996;Germann, 1996) 2. alterations in β-tubulin isotypes (Haber et al, 1995;Ranganathan et al, 1988Kavallaris et al, 1997 3. mutations in tubulins (Cabral et al, 1981;Schibler and Cabral, 1986;Giannakakou et al, 1997) 4. up-regulation of caveolin-1 (Yang et al, 1998.Paclitaxel also activates molecules that are involved in signal transduction pathways such as c-jun N-terminal kinase (Blagosklonny et al, 1995;Wolfson et al, 1997;Wang et al, 1998).Annexins are a family of calcium-dependent phospholipid binding proteins. There are at least 13 annexin family members with a similar structure, characterized by the presence of four or eight repeats of a 70 amino acid motif and a variable N-terminal end (Smith and Moss, 1994;Dubois et al, 1996;Benz-and Hofmann, 1997). Although the roles of the annexins are not well understood, they have been involved in various biological processes including inhibition of phospholipase A2, anticoagulation, endocytosis, exocytosis, inhibition of calcium channels and protein kinase C activity (Smith and Moss, 1994). It was also previously shown that annexin II was elevated in doxorubicin-resistant small-cell lung cancer cell line (Cole et al, 1992). During the course of our antimitotic research, we found that annexin IV was overexpressed in A204197-resistant human colon cancer HCT-15 cells as determined by two-dimensional protein mapping as well as mass spectroscopic analysis. Therefore, we tested whether annexin IV or annexin II was also overexpressed in a paclitaxel-resistant cell line, H460/T800. To our surprise annexin IV, but not annexin II, was overexpressed in the paclitaxel-resistant H460 lung cancer cell line. To further confirm the role of annexin IV in drug resistance, annexin IV cDNA was transfected into 293T cells. Annexin IV transfectants were more resistant to paclitaxel as compared to the vector controls. Thus our study indicates that annexin IV plays a role in regulating paclitaxel resistance. MATERIALS AND METHODS Cell cultureLung cancer cell line NCI-H460 (hereafter referred to as H460) and colon cancer cell line HCT15 were obtained from the American Tissue Culture Collection (ATCC) H460 and HCT15 cells were grown and maintained in RPMI medium plus 10% fetal bovine serum (FBS) or 20% FBS respectively. Paclitaxel-resistant cell lines were derived from the H460 parental cell line. H460 cells were initially selected with IC 50 concentration of paclitaxel and thereafter paclitaxel concentration was doubled every 2-3 weeks until 800 nM paclitaxel resistance was obtain...

show abstract

Section: Discussioncontrasting

confidence: 75%

Section: Annexin IV Overexpression In Paclitaxel-resistant H460 Cell mentioning

confidence: 97%

mentioning

confidence: 99%

See 1 more Smart Citation

Modulation of paclitaxel resistance by annexin IV in human cancer cell lines

Han¹,

Tahir²,

Cherian³

et al. 2000

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…However, more identified genes should be further confirmed. Annexin A2 was found in transformed cells as a substrate of pp60 src tyrosine kinase [19], and annexin A2 up-expression is observed in pancreatic adenocarcinoma [20], human hepatocellular carcinoma [21], and a multidrug-resistant, smallcell lung cancer cell line [22]. Annexin A2 is part of the primer recognition protein complex that interacts with DNA polymerase a in lagging strand DNA replication [23].…”

Section: Discussionmentioning

confidence: 99%

Identification of differentially expressed genes in clear cell renal cell carcinoma by analysis of full-length enriched cDNA library

et al. 2006

View full text Add to dashboard Cite

SummaryRenal cell carcinoma (RCC) is the most common malignancy in adult kidney, and accounts for 3% of malignancies worldwide with increasing incidence. Clear cell RCC (ccRCC) is the major type in RCC. Resection by surgery is the main treatment because the response of ccRCC to traditional therapies is very poor. To identify the tumor-associated genes for better understanding the molecular mechanism of ccRCC, the full-length enriched cDNA libraries of ccRCC and normal kidney tissues were constructed by the oligo-capping method. Nucleotide sequences of the cDNA libraries of ccRCC and normal kidney tissues were sequenced. From the sequence analysis of 19,425 and 12,400 clones of ccRCC and normal kidney tissues, 4356 and 3055 genes were identified, respectively. By comparing the gene-expression patterns of ccRCC and normal tissues, the up-or down-regulated genes were identified. Among these identified genes, the differential expression of annexin A2 and argininosuccinate synthetase genes were further confirmed by quantitative real-time PCR and Western blot analysis.

show abstract

“…Fewer HSCs are found in the marrow of Anxa2 deficient mice thus indicating that Anxa2 acts as an adhesion ligand for HSC homing [89]. Anxa2 is also associated with proliferative and invasive cancers including lung, pancreatic, brain, colon and gastric carcinomas, and is associated with poor prognosis [90][91][92][93]. It was shown that Anxa2 expressed by the osteoblasts serves as an adhesion molecule for prostate cancer cells.…”

Section: Chemotaxis Towards Bonementioning

confidence: 99%

Homing of Cancer Cells to the Bone

Mishra

Shiozawa

Pienta

et al. 2011

Cancer Microenvironment

View full text Add to dashboard Cite

A variety of tumor cells preferentially home to the bone. The homing of cancer cells to the bone represents a multi-step process that involves malignant progression of the tumor, invasion of the tumor through the extracellular matrix and the blood vessels and settling of the tumor cells in the bone. Gaining a greater understanding as to the mechanisms used by cancer cells in these processes will facilitate the design of drugs which could specifically target the homing process. In this review we will discuss the properties of tumor cells and the bone microenvironment which promote homing of a cancer cell to the bone. We will highlight the different steps and the molecular pathways involved when a cancer cell metastasize to the bone. Since bone is the major home for hematopoietic stem cells (HSCs), we will also highlight the similarities between the homing of cancer and HSC to the bone. Finally we will conclude with therapeutic and early detection strategies which can prevent homing of a cancer cell to the bone.

show abstract

Elevated expression of Annexin II (Lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line

Cited by 88 publications

References 41 publications

Modulation of paclitaxel resistance by annexin IV in human cancer cell lines

Modulation of paclitaxel resistance by annexin IV in human cancer cell lines

Identification of differentially expressed genes in clear cell renal cell carcinoma by analysis of full-length enriched cDNA library

Homing of Cancer Cells to the Bone

Contact Info

Product

Resources

About